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Abstract
Backgrounds: By a new concept called “phase diagram”, we compare two commonly used genotype-
based tests for case-control genetic analysis, one is a Cochran-Armitage trend test (CAT test at x = 0.5, or
CAT0.5) and another (called MAX2) is the maximization of two chi-square test results: one from the two-by-
two genotype count table that combines the baseline homozygotes and heterozygotes, and another from the
table that combines heterozygotes with risk homozygotes. CAT0.5 is more suitable for multiplicative disease
models and MAX2 is better for dominant/recessive models. Methods: We define the CAT0.5-MAX2 phase
diagram on the disease model space such that regions where MAX2 is more powerful than CAT0.5 are separated
from regions where the CAT0.5 is more powerful, and the task is to choose the appropriate parameterization
to make the separation possible. Results: We find that using the difference of allele frequencies (δp) and
the difference of Hardy-Weinberg disequilibrium coefficients (δǫ) can separate the two phases well, and the
phase boundaries are determined by the angle tan−1(δp/δǫ), which is an improvement over the disease model
selection using δǫ only. Conclusions: We argue that phase diagrams similar to the one for CAT0.5-MAX2
have graphical appeals in understanding power performance of various tests, clarifying simulation schemes,
summarizing case-control datasets, and guessing the possible mode of inheritance.
1
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Introduction
Comparing allele and genotype frequencies of a single marker between the patients and
normal people (Sasieni, 1997; Lewis, 2002; Li, 2008) remains the core of a case-control genetic
association analysis, prior to a haplotype analysis and bioinformatic analysis to determine
the spatial extent and gene context of the signal. The success of a genetic association study
crucially depends on study design (Amos, 2007), but the choice of test is also somewhat
important. If we focus on genotype-based tests, i.e., each observed genotype is a sample instead
of two allele samples (Sasieni, 1997), there are many possible types of tests to choose from.
For example, the Pearson’s goodness-of-fit test on the 2-by-3 genotype count table, Cochran-
Armitage trend (CAT) tests with a single parameter value x which determines the relative risk
of heterozygote with respect to the two homozygotes (Sasieni, 1997; Devlin and Roeder, 1999;
Slager and Schaid, 2001), tests that are maximized over two or more tests (Yamada et al., 2001;
Freidlin et al., 2002; Tokuhiro et al., 2003; Zheng et al., 2006a), and those that stepwisely use
a few tests sequentially (Zheng et al., 2008). This quote from (Balding, 2006) might capture
the feeling about the current state: “there is no generally accepted answer to the question of
which single-(marker) test to use” in genetic case-control association analysis. The widespread
use of whole-genome association in the study of complex diseases nowadays (Wellcome Trust
Case Control Consortium, 2007) adds an urgency in having a better understanding of this
issue.
If one statistical test is always more powerful than another test, the first test should of course
be used all the time. However, each test may have its own strength and weakness depending
on the true underlying model. For example, Cochran-Armitage trend as a family of tests is to
test the equality of genotype frequencies in the case and the control group, but as a test at a
parameter x is to test the null hypothesis Pcase(AA)+xPcase(Aa) = Pcontrol(AA)+xPcontrol(Aa)
(AA is the risk genotype, and P (AA) is its frequency; similarly for heterozygous genotype Aa).
The CAT test at x = 0 is most powerful for detecting recessive disease genes, whereas it is
more powerful at x = 0.5 when Hardy-Weinberg equilibrium (HWE) holds for case and control
groups. For a pair of tests, in the space of all possible disease models, the first test can be more
powerful in some regions whereas the second test is more powerful in other regions. This simple
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picture is reminiscent of the phase diagram in physics (e.g., Gibbs, 1873; Lifshitz and Landau,
1980) where a phase can be solid, liquid or gas depending on the temperature, pressure, or
other relevant quantities. In our case-control genetic test example, the aim of phase diagram
is to graphically depict regions where specific test is more powerful than others. Note that one
should not confuse the usage of “phase” here with the meaning often used in genetics, i.e., of
the “parental origin” of an allele in a genotype (e.g. Scheet and Stephens, 2006).
Although the principle of our phase diagram can be established as discussed above, there
are several practical considerations. First, a disease model is specified by many parameters,
and one may wonder whether the phase structure can be seen in a two-dimensional space.
Second, if the two phases are highly intermingled in one parameterization, we may ask if other
parameterization schemes are better suited for separating the two phases. Third, besides the
definition of phases which are based on statistical power, we can also define phases that are
based on p-value, and the question is whether the two ways of defining phase diagrams are
similar. This paper uses a specific pair of tests to address these questions and to show the
utility of this approach.
The motivation of our study is to discuss the issue of in what circumstances, one should
use a particular test instead of others. We first study the parameterization of phase diagram,
then construct two phase diagrams, one power-based and another p-value-based, for a pair of
commonly used tests. The phase boundary in both versions of phase diagram will be deter-
mined. And we examine several whole-genome association datasets using the phase diagram.
Several other applications of the phase diagram are also discussed, including comparison of
two random simulations of disease models, and graphical display of case-control data of many
SNPs.
Methods
Case-control difference of allele frequency and Hardy-Weinberg disequilibrium
(HWD) coefficient given a disease model
A single-locus biallelic disease model can be specified by four parameters: three penetrances
fi =Prob(disease|Gi) (i = 0, 1, 2) where {Gi} are the three genotypes aa, aA,AA, and the
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population A-allele frequency p. Alternatively, one can use the allele frequency p, two relative
genotype risks λi = fi/f0 (i = 1, 2), and disease prevalence K = f0[(1−p)2+2p(1−p)λ1+p2λ2]
to specify the disease model. Denote A-allele frequency in case and control group as p1 and p0,
and HWD coefficient (Weir, 1996) in case and control group as ǫ1 and ǫ0; all four (p1, p0, ǫ1, ǫ0)
can be derived from a given disease model, under the assumption that HWE holds true for
the general population that contains both cases and controls (Wittke-Thompson et al., 2005).
We use the difference of A-allele frequency (δp) and the difference of HWD coefficients (δǫ) in
case and control group as the parameters for our phase diagram:
δp ≡ p1 − p0 = f0(p
2λ2 + p(1− p)λ1)
K
− p
2(1− f0λ2) + p(1− p)(1− f0λ1)
1−K
δǫ ≡ ǫ1 − ǫ0 = f
2
0
p2(1− p)2(λ2 − λ21)
K2
− f0p
2(1− p)2(2λ1 − 1− λ2 − f0λ21 + f0λ2)
(1−K)2
(1)
When λ1 > 1 and λ2 > 1, A-allele is enriched in the case group, and δp is always positive. On
the other hand, if λ1 < 1 and λ2 < 1, A-allele is depleted in the case group and δp is negative.
To be consistent, we call A the risk allele when δp > 0. Whether A-allele is a minor allele
(p < 0.5) or a major allele (p > 0.5) does not by itself affect the sign of δp and δǫ.
Case-control difference of allele frequency and Hardy-Weinberg disequilibrium co-
efficient given a genotype count table
Table 1(A) shows a case-control genotype count table {Nij} (i =1,0 for case, control, and
j =0,1,2 for genotypes with 0, 1, 2 copies of allele A) with total N = N1 + N0 samples.
The same table is parameterized in Table 1(B) using the estimated {pˆi} and {ǫˆi} (i =1,0 for
case, control). The estimated A-allele frequency (δˆp) and the estimated difference of HWD
coefficients (δˆǫ) in case and control group can be obtained from Table 1(A) as:
δˆp = pˆ1 − pˆ0 = N11/2 +N12
N1
− N01/2 +N02
N0
δˆǫ = ǫˆ1 − ǫˆ0 = N12
N1
−
(
N11/2 +N12
N1
)2
− N02
N0
+
(
N01/2 +N02
N0
)2
(2)
For notation simplicity, the hat (ˆ) will be removed later on, and whether the model-based or
data-based usage is applied should be clear from the context.
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Note that switching the A and a allele, or equivalently, switching the first and the third
column in Table 1, changes the sign of δp, whereas the sign of δǫ is unaffected. Eq.(2) also
shows another advantage of using the difference of two HWD coefficients: if the disequilibrium
is sensitive to typing errors, its effect is minimized when the difference δˆǫ is used.
Cochran-Armitage trend test and MAX2 test
Cochran-Armitage trend (CAT) test at parameter x assigns a score of 0, x, and 1 for
genotypes aa, aA, and AA, for log-risk relative to the baseline aa genotype (Sasieni, 1997;
Devlin and Roeder, 1999; Slager and Schaid, 2001). Sometimes, the name of Cochran-Armitage
trend test is used to only refer to that at parameter x = 0.5 (Balding, 2006), which we will call
as CAT0.5. On the other hand, CAT at parameter settings of x = 0 and x = 1 is equivalent
to assuming recessive and dominant models, which we will refer to as CAT0 and CAT1.
With the genotype count in Table 1, the test statistic of CAT0.5, CAT0, and CAT1 can be
derived (see, e.g., Sasieni, 1997). We re-parameterize these test statistics using a new set of
parameters including δp and δǫ:
X2(CAT0.5) =
N1N0
N
· 2δ
2
p
p+ p2 − 2p2 + ǫ
X2(CAT0) =
N1N0
N
· (2
=
p δp + δǫ)
2
(p2 + ǫ)(1− p2 − ǫ)
X2(CAT1) =
N1N0
N
· (2(1−
=
p)δp − δǫ)2
(2p− p2 − ǫ)(1− 2p+ p2 + ǫ) (3)
where δp ≡ p1 − p0, p ≡ (N1/N)p1 + (N0/N)p0, p2 ≡ (N1/N)p21 + (N0/N)p20, ǫ ≡ (N1/N)ǫ1 +
(N0/N)ǫ0,
=
p≡ (p1+ p0)/2. CAT0.5 usually leads to very similar result to the allele-based test.
But since CAT0.5 is a genotype-based test, it does not have the problem of allele-based test
for artificially doubling the sample size (Sasieni, 1997).
The MAX2 test is defined by the maximization of the CAT0 and CAT1 test statistics:
X2(MAX2) ≡ max(CAT0, CAT1). Although MAX2 has been used in a few analyses (e.g.,
Yamada et al., 2001; Tokuhiro et al., 2003), it did not have a formal name. The name of MAX2
used here is to distinguish it from the MAX3 test (max(CAT0, CAT1, CAT0.5)) proposed in
(Freidlin et al., 2002).
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Since MAX2 involves a multiple testing whereas CAT0.5 does not, its p-values are calculated
differently. For CAT0.5, the p-value is simply derived by the χ2 distribution with 1 degree of
freedom. For MAX2, Dunn-S˘ida´k multiple testing correction (Ury, 1976) is exact if CAT0 and
CAT1 test statistics were independent:
pMAX2 = P0(X
2(MAX2) > T ) = 1− P0(X2(MAX2) < T ) = 1− P0(X2 < T )2
= 1− (1− pX2)2 = 2pX2 − p2X2 (4)
where P0 is the null distribution, pX2 is the p-value for a χ
2-distributed test statistic. In R code
(http://www.r-project.org/), the command for calculating p-value for MAX2 is 1-pchisq(MAX2,
df=1)^2.
For dataset generated by a known disease model, CAT test statistics follow chi-square
distributions with non-central parameters. The non-central parameters for CAT0.5, CAT0
and CAT1 are given in Eq.(3), only that δp, δǫ, and other parameters are determined by the
disease model, not from the data. Alternatively, power can be determined empirically by
simulation.
Simulation
For empirical power calculation, we sampled Nr (=5000) replicates of genotypes for Ncase
(=500) cases and Ncontrol (=500) controls, given a disease model. In Fig.2, Nm (=10000)
disease models were generated randomly. The relative genotype risks λ1 and λ2 are randomly
selected from a range (e.g., (0.5-2)), and the population A-allele frequency is randomly selected
(e.g., from (0.1-0.9)). The type I error is set at 0.05 and we have determined the test statistic
threshold for MAX2 either by permutation or by Dunn-S˘ida´k formula. Due to the consistency
between the two approaches, the type I error is controlled mostly by using the Dunn-S˘ida´k
formula in Eq.(4). The empirical power of CAT0.5 or MAX2 at the given type I error is
determined by the proportion of replicates that exceeds the threshold.
For the phase diagram in Fig.4 under the null model (i.e., same allele and genotype frequency
according to the HWE), Nr (=2000) replicates of genotype were generated for Ncase (=500)
cases and Ncontrol (=500) controls.
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Results
Phase diagrams based on power given the disease model
In the δǫ-δp space, known types of disease models such as dominant, recessive, additive,
multiplicative, and over-dominant models fall in different regions of the plane, after requiring
the risk allele A to have higher frequency in cases than in controls, as can be seen from Fig.1.
For example, recessive models reside in the first quadrant, additive, dominant, over-dominant
models are in the second quadrant, and the multiplicative models sit along the y-axis.
We pick CAT0.5 and MAX2 as the two tests to compare for the following reasons. First,
allele-based test is still one of the most commonly used tests in case-control genetic analysis,
and we would like to choose a similar genotype-based test. Second, we want to choose a test
that is robust against disease model mis-specification. These two considerations lead to CAT0.5
and MAX2. Fig.2 shows the power-based CAT0.5-MAX2 phase diagram, where empirically
obtained statistical power of CAT0.5 and MAX2 are compared while controlling the type I
error, in the space parameterized by δǫ and δp.
The region in Fig.2 where power(MAX2) > power(CAT0.5), or phase 1, covers most of the
model space. On the other hand, region where power(CAT0.5) > power(MAX2), or phase 2,
is limited to a narrow angle around the y-axis. For regions far away from the x-axis, both
tests lead to close to 100% power (the symbol “1” is used to mark the points when both
power(CAT0.5) and power(MAX2) are larger than 0.99). The phase boundary in the first
(and the third) quadrant can be roughly approximated by the line θ = tan−1(δp/δǫ) = 73.125
◦
(13π/32). The phase boundary in the second (and the fourth) quadrant is not sharp with
some degree of overlap between the two phases. However, the line θ = tan−1(δp/δǫ) = 106.875
◦
(19π/32) seems to provide a reasonable boundary to phase 2 points.
The phase structure presented in Fig.2 is consistent with our current knowledge that allele-
based test and CAT0.5 are most powerful for multiplicative models. In fact, it can be shown
that non-central parameter in the χ2 distribution for the allele-based test is strictly larger than
that of either CAT0 or CAT1 (i.e., either one of two ways to combine heterozygote counts with
the homozygote counts), if (1) ǫ1 = ǫ0 = 0 and (2) N1 = N0 (Suh and Li, 2007). However, it
was somewhat surprising that the two phases in Fig.2 are not separated by vertical lines. The
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two-phase genetic model selection method proposed in (Zheng and Ng, 2008) attempts to infer
the underlying disease model by δǫ value alone. Here we show that the model selection could
be more accurate if both δǫ and δp parameters are considered.
To have a better understanding of the phase structure, in Fig.3, we plot the power of CAT0.5
as a function of |δp| as well as power of MAX2 as a function of radius
√
δ2p + δ
2
ǫ . As expected,
the power of CAT0.5 increases as the allele frequency difference is larger, because CAT0.5 is
very close to the allele-based test which is designed to detect allele frequency differences. On
the other hand, it was unexpected that the power of MAX2 increases with the radius, and the
increase follows a similar way as power of CAT0.5 increases with |δp|. If we draw the two plots
in one, the two more or less overlap. In a crude approximation, suppose power(CAT0.5) vs.
|δp| and power(MAX2) vs.
√
δ2p + δ
2
ǫ follow the same functional form, then the power of MAX2
should be larger than that of CAT0.5 over the whole plane except the y-axis, because radius is
always larger than the y value except for the y-axis. Although this is only an approximation,
Fig.3 helps us to understand why the robust MAX2 test is more likely to be more powerful
than the CAT0.5 test in the space of all possible models.
Phase diagrams based on p-values given the genotype data
Power analysis is always discussed in a theoretical context because it requires our knowing
of the true disease model. In reality, the disease model is not supposed to be known. Towards a
data-driven concept of phase diagram, we define the following phase diagram based on p-values.
As can be seen from Eq.(3), the relative magnitude of CAT0.5 and MAX2 test statistics
depends on the estimated value of four parameters p1, p0, ǫ1, ǫ0, as the common factor N1N0/N
is canceled out. If we assume that averaged quantities such as p and ǫ do not vary dramati-
cally with different p1, p0, ǫ1, ǫ0 values, then the relative magnitude of CAT0.5 and MAX2 test
statistics are mainly determined by the parameters δp and δǫ.
Because of the multiple testing in MAX2, even if a MAX2 test statistic is larger than that
of CAT0.5, the MAX2 p-value may not be smaller than the p-value by CAT0.5. It should
be noted that the assumption to apply Dunn-S˘ida´k formula in Eq.(4), i.e., the independence
between the two terms to be maximized, does not hold exactly. However, the correlation
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between CAT0 and CAT1 is actually small. It was shown in (Freidlin et al., 2002; Zheng et al.,
2006a) that the correlation between CAT0 and CAT1 test statistics under the null hypothesis
(p1 = p0), if HWE is true, is
√
p1(1− p1)/[(1 + p1)(2− p1)]. This correlation is at most 1/3
which is reached when p1 = p0 = 0.5. Simulation shows that Dunn-S˘ida´k formula leads to an
accurate estimation of pMAX2, despite a weak violation of the assumption. This is in a contrast
with MAX3, where the correlation between CAT0.5 and either CAT1 or CAT0 is too strong
to apply the Dunn-S˘ida´k formula (Gonza´lez et al., 2008; Li et al., 2008).
Fig.4 shows the phase diagram based on comparing p-values of CAT0.5 and MAX2 when
genotype count tables are randomly sampled from the null model. The MAX2 (CAT0.5) test
is preferred over CAT0.5 (MAX2) in phase 1 (2) because it has a smaller p-value (black (grey)
dots). When we draw the same straight lines as Fig.2 with 73.125◦ and 106.875◦, a similar
observation can be made that the phase separation is much better in the first (and the third)
quadrant, and a low level of overlap occurs in the second (in the fourth) quadrant. We conclude
that the CAT0.5-MAX2 phase diagram based on p-values is very similar to the CAT0.5-MAX2
phase diagram based on power. Because the ranges of x and y in Fig.4 are smaller than those
in Fig.2, another understanding of p-value-based phase diagram is that it is the “extension”
of power-based phase diagram towards the origin.
Illustration of the CAT0.5-MAX2 phase digram by results of several genome-wide
association studies
Recently, the largest scale whole-genome association study was carried out by Wellcome
Trust Case Control Consortium on several common complex diseases (Wellcome Trust Case
Control Consortium, 2007). We take the genotype count for SNPs that showed the strongest,
and for many of them, validated association signal using extra samples, to illustrate the use of
phase diagram. The association signal in (Wellcome Trust Case Control Consortium, 2007) s
mainly ranked by the CAT0.5 test.
Table 2(A) lists the raw genotype count data of 11 SNPs that are associated with one of
these diseases: ankylosing spondylitis (Wellcome Trust Case Control Consortium & Australo-
Anglo-American Spondylitis Consortium, 2007), type 1 diabetes (Todd et al., 2007), Crohn’s
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disease (Parkes et al., 2007), and type 2 diabetes (Zeggini et al., 2007). Table 2(B) shows
the estimated case or control minor allele frequency (p1, p0) and their difference (δp), case or
control HWD coefficients (ǫ1, ǫ0) and their difference (δǫ), the angle θ in the δp − δǫ phase
diagram with respect to either x or y axis, and CAT test statistics at x = 0.5, 0, 1.
There are several observations made from Table 2(B). As expected, the estimated HWD co-
efficient in case group ǫ1 is usually larger in magnitude than that in control group ǫ0. However,
the largest observed ǫ1 is only around 0.01. On the other hand, allele frequency difference is
large (0.03-0.07) due to the fact that these SNPs are selected by significant CAT0.5 test. A
consequence of the two facts is that the angle with respect to the y-axis in Table 2(B) tends to
be small, with the exception of SNP rs27044 which is associated with ankylosing spondylitis
(θ − 90◦ = 16.4◦).
The closeness to the y axis of these SNPs on the phase diagram should indicate, on average,
CAT0.5 test to be better than MAX2 test. Indeed, the X2(CAT0.5) test statistics are larger
than X2(MAX2) except for two SNPs: rs27044 and rs2542151. It is not surprising to see
rs27044 in the exception list as it has the largest angle with respect to the y-axis, and the
negative sign of δǫ indicates that the disease model for rs27044 is more likely dominant. For
rs27044, MAX2 test leads to a more significant result (p-value = 1.8 ×10−7) than the CAT0.5
test (p-value= 10−6). For rs2542151, its position in the phase diagram forms a smaller angle
with the y-axis than the rs27044 SNP (8.5◦ vs. 16.4◦), but the angle is still large enough such
that MAX2 leads to a more significant test (p-value =3.7× 10−14) than CAT0.5 test (p-value
= 1.9× 10−13).
Discussion and conclusions
Our choice of δp is to capture the linear or first-order term from the disease model or data,
and δǫ to capture the nonlinear or second-order term. In quantitative genetics, there is a
similar approach in using the additive variance σ2a and dominance variance σ
2
d (Fisher, 1918;
Falconer and Mackay, 1996). When these concepts from quantitative genetics are translated to
dichotomous traits, σ2a = 2p(1−p)(p(f2−f1)+(1−p)(f1−f0))2, and σ2d = p2(1−p)2(f2+f0−2f1)2
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(see, e.g., Blackwelder and Elston, 1985). Using Eq.(1), we have
δp =
f2 −K
K(1−K)p
2 +
f1 −K
K(1−K)p(1− p)
=
pf2 + (1− p)f1 −K
K(1−K) · p =
p(f2 − f1) + q(f1 − f0)
K(1−K) · p(1− p). (5)
In other words, the square of our first-order parameter δ2p is proportional to the additive
variance σ2a. Similarly, using Eq.(1) for δǫ, we have
δǫ = p
2(1− p)2
(
1
K2
− 1
(1−K)2
)
(f2f0 − f1) +
(
p(1− p)
1−K
)2
(2f1 − f2 − f0)
=
p2(1− p)2(1− 2K)
K2(1−K)2 (f2f0 − f
2
1
) +
p2(1− p)2
(1−K)2 (f2 + f0 − 2f1). (6)
When the disease prevalence K is low, δǫ is roughly proportional to f2f0 − f 21 , as versus the
f2 + f0 − 2f1 expression in σ2d. Actually, the HWD coefficient in the control group, which
is small, is proportional to the difference between f2f0 − f 21 and f2 + f0 − 2f1, and two are
approximately equal when λ1, λ2 are small (Zheng et al., 2006b). Crudely, the square of δǫ can
be said to be proportional to the dominance variance σ2d.
The idea to use the test that is most powerful to the underlying model sounds straightfor-
ward, but in reality the true disease model is unknown. There have been attempts to infer
the disease model by the HWD information. For example, (Wittke-Thompson et al., 2005)
distinguishes HWD from different disease models and proposed its use for data fitting (note
that the additive model defined in (Wittke-Thompson et al., 2005), λ2 = 2λ1, is different from
that defined here, f2 − f1 = f1 − f0 or λ2 = 2λ1− 1). In (Zheng and Ng, 2008), the signs of ǫ1
and ǫ0 are used for genetic model selection: (+,−) for recessive models, (−,+) for dominant
models, and (−,−) for multiplicative and additive models. Since the amount of HWD in con-
trol group is usually much smaller than that in case group, the sign of δǫ = ǫ1 − ǫ0 ≈ ǫ1 may
serve the purpose in selecting recessive and dominant models. All these previous works use
HWD alone in genetic model selection, without considering a joint effect of HWD and allele
frequency difference.
The result discussed in this paper shows that a joint consideration of δǫ and δp could be
more effective, than a consideration of δǫ only, in selecting disease model. The following
simple procedure might be reasonable: first draw a line from origin to the data-determined
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(x, y) = (δǫ, δp) position, then calculate the angle formed by this line and the y-axis. If the angle
is smaller than 3π/32 (or 16.875◦), the underlying model is more likely to be multiplicative
and CAT0.5 is the preferred test to use. On the other hand, if the angle with respect to
the y-axis is larger, the underlying model is more likely to be recessive (if it’s in the first
quadrant) or dominant (second quadrant), and MAX2 is preferred over CAT0.5. A caution on
this procedure is that, unless the sample size is very large and unless the true model is away
from the phase transition line, the disease model can still be incorrectly inferred.
Comparing the power of two tests is always tricky because the answer depends on what
is known about the true model. It is very much in the spirit of Bayesian statistics that the
posterior probability distribution depends on the prior. Any claim on discovering a more
powerful test may contain a caveat on how the alternative model is sampled. Phase diagram
discussed here provides a framework to visually inspect distributions on the δp-δǫ, for the
simulated models,
Fig.5 shows the distribution on the phase diagram of two different ways of simulating
genotype count tables. The first is by randomly sampling two allele frequencies pcase and
pcontrol that are close to each other (difference is less than 0.1), then the genotype frequencies
in the model are determined by the HWE. One such model is used to generate one replicate
dataset and δǫ, δp values are determined from the replicate. The second way to generate a
random model is to randomly sample two sets of genotype frequencies, for case and control
group, that are close to each other (difference is less than 0.1), and that model is used to
simulate one replicate dataset.
When we compare the empirical power of MAX2 and MAX3, MAX3 is more powerful than
MAX2 in the first simulation, whereas MAX2 is slightly more powerful than MAX3 in the
second simulation. The phase diagram in Fig.5 easily solves the puzzle: from Fig.5, it can
be seen that simulated datasets by the first method centered around the y-axis, as genotype
frequencies in the model are obtained by HWE, whereas those by the second method are more
widespread in the x-axis. If we require a graphic showing of the phase diagram like Fig.5 in
any power comparison between two tests, there would be less misunderstanding of seemingly
conflicting empirical results.
The phase-diagram can also be used to summarize a case-control dataset with many SNPs.
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Fig..6 shows 2147 SNPs on chromosome 18q21 for 460 cases and 459 controls used in Genetic
Analysis Workshop 15 (Amos et al., 2007; Wilcox et al., 2007), with δˆp and δˆǫ calculated by
Eq.(2). These SNPs are filtered from the original list of 2719 SNPs by requiring no more than
10 missing typings and minor allele frequency to be larger than 0.05. For some SNPs, alleles
are switched to make sure δp is positive. One striking visual impression of Fig.6 is that the
SNPs with the largest δp values are not located on y-axis, but in the first quadrant, indicating
that recessive model better describes the effect of these SNPs than the multiplicative model.
In Fig.6, the SNP rs3745064 at position 53.305Mb exhibits the largest δp value (=0.076)
(Kuo et al., 2007; Tapper et al., 2007). The distribution of case samples among the three
genotypes is 37, 180, 243, and that of control samples is 50, 223, 186, leading to p1 = 0.724,
p0 = 0.648, δ1 = 0.0042, δ0 = −0.015. For this SNP, we expect the largest test statistic value
to be CAT(x = 0) because it is located in the first quadrant on the phase diagram. Indeed,
CAT(x = 0)=13.97, CAT(x = 0.5)=12.47, CAT(x = 1)=2.18, and MAX2 test statistic is more
powerful than CAT(x = 0.5).
Using the phase diagram to examine the most recent whole-genome association data shows
that SNPs with the strongest association signal tend to be multiplicative, and CAT0.5 test is
more powerful than MAX2 test in this situation. However, we should not exclude the possibility
that it is due to a selection bias, as the top ranking genes were chosen by CAT0.5 test result.
Also, if the most significant SNPs exhibit larger allele frequency differences, whereas their δǫ
value is limited, their positions in the phase diagram is expected to be closer to the y-axis.
Whether the result in Table 2(B) is due to selection bias or not, our approach could be
useful in analyzing whole-genome association data, as illustrated by Fig.6. Applying MAX2
may change the rank order of some SNPs that are near the top, and consequently change
the pool of SNPs to be studied further. If MAX2 test does improve the p-value over CAT0.5
for a SNP, one can check whether the HWD mainly occurs in the case instead of the control
group. The location of a SNP on the phase diagram provides a quick filtering of SNPs where
the inclusion of non-multiplicative models may improve the association signal, such as the
example of rs3745064 on Fig.6. Due to a high cost of typing extra samples in validating the
associated SNPs for the second round, it is important to carry out careful analyses including
the consideration of alternative disease models.
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In conclusion, using the phase diagram is to partition the violation of null hypothesis of
equal genotype frequency in case and control groups into two components, one δp for allele
frequency difference and another δǫ for difference in HWD coefficients. The relative magnitude
of δp and δǫ determines which test, e.g., between CAT0.5 and MAX2, is more powerful. The
phase diagram highlights the point that no uniformly powerful test exists, and a test is only
more powerful regionally in the model space. We believe the use of phase diagram can aid the
design of test when some knowledge of the mode of inheritance is available, as well as inferring
the underlying mode of inheritance from the data.
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(A) genotype count table
sample size aa aA AA
case(1) N1 N10 N11 N12
control(0) N0 N00 N01 N02
(B) same genotype count table parameterized by p1, p0, ǫ1, ǫ0
aa aA AA
case(1) N1[(1 − p1)2 + ǫ1] N1[2(1− p1)p1 − 2ǫ1] N1[p21 + ǫ1]
control(0) N0[(1 − p0)2 + ǫ0] N0[2(1− p0)p0 − 2ǫ0] N0[p20 + ǫ0]
Table 1: Genotype count table (A) and its parameterization using p1, p0, ǫ1, ǫ0 (B).
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(A) genotype count table
disease gene SNP chromosome case(aa/aA/AA) control (aa/aA/AA)
ASa ARTS1 rs27044 5 793/553/119 395/432/94
AS LNPEP rs2303138 5 738/176/8 1269/193/4
T1Db C12orf30 rs17696736 12 1984/3115/1168 1545/2891/1373
T1D ERBB3 rs2292239 12 2592/2805/801 1956/2816/946
T1D KIAA0350 rs12708716 16 2652/2857/779 2834/2429/569
T1D PTPN2 rs2542151 18 4219/1635/182 3628/1889/220
T1D PTPN22 rs2476601 1 4674/998/55 3754/1580/178
CDc IRGM rs13361189 5 2061/705/59 8907/1476/54
CD NOD2 rs17221417 16 1505/1175/256 747/754/245
CD IL23R rs11805303 1 1385/1236/313 655/815/276
T2Dd FTO rs8050136 16 1063/1407/464 550/987/378
(B) position on the phase diagram
disease/SNP p1 p0 δp ǫ1 ǫ0 δǫ θ θ − 90◦ CAT(0.5/0/1)
AS/rs27044 .34 .27 .067 −.011 .0083 −.020 106.4 16.4 23.9/3.0/28.6
AS/rs2303138 .069 .10 −.036 −.0020 −.0022 2× 10−4 −89.7 0.3 19.4/4.0/17.9
T1D/rs17696736 .49 .43 .050 9× 10−4 −.0028 .0037 85.8 -4.2 61.5/45.3/37.3
T1D/rs2292239 .41 .36 .056 −.004 .0028 −.0069 97.0 7.0 79.3/31.2/73.0
T1D/rs12708716 .31 .35 −.045 .004 6× 10−4 .0034 −85.7 4.3 55.4/21.2/50.3
T1D/rs2542151 .20 .17 .037 −.0029 .0027 −.0056 98.5 8.5 54.7/5.6/58.7
T1D/rs2476601 .18 .097 .079 .0015 2× 10−4 .0012 89.1 -0.9 292.6/71.2/273.2
CD/rs13361189 .076 .15 −.070 −6× 10−4 −3× 10−4 −3× 10−4 −90.2 -0.2 261.5/65.0/238.4
CD/rs17221417 .36 .29 .069 .013 .0047 .0088 82.8 -7.2 46.5/32.3/31.5
CD/rs11805303 .39 .32 .074 .0048 .0060 −.0012 90.9 0.9 51.7/26.3/41.8
T2D/rs8050136 .46 .40 .057 −.0097 −2× 10−4 −.0095 99.5 9.5 31.4/12.4/29.4
Table 2: (A) Genotype counts of SNPs that show strong (and validated) association signal with several
common diseases. a. ankylosing spondylitis (Wellcome Trust Case Control Consortium & Australo-Anglo-
American Spondylitis Consortium, 2007). b. type 1 diabetes (Todd et al., 2007). c. Crohn’s disease (Parkes et
al., 2007). d. type 2 diabetes (Zeggini et al., 2007). Other information includes gene and SNP name, as well as
the chromosome number on which the SNP is located. (B) For the SNP listed in (A), minor allele frequency
in case (p1) and control (p0) group, their difference (δp = p1 − p0), HWD coefficients in case (ǫ1) and control
(ǫ0) group, and their difference (δǫ = ǫ1− ǫ0), angle θ = tan−1(δp/δǫ) in the phase diagram, angle with respect
to the y-axis (θ − 90◦ if θ > 0, or θ + 90◦ if θ < 0), and test statistics for CAT0.5, CAT0, CAT1.
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Figure 1: Locations in the phase diagram parameterized by x = δǫ and y = δp for some commonly encountered
disease models, recessive (R/r), dominant (D/d), additive (A/a), multiplicative (M/m) and over-dominant
(O/o). The upper case is used when the power of MAX2 is larger than the power of CAT0.5, and lower case for
the opposite. The model parameters are sampled from these ranges, population A-allele frequency is randomly
sampled from (0-0.5), phenocopy rate f0 from (10
−6-10−3), with the exception of over-dominant models, λ2
from (1.001-2) and λ1 is derived from λ2 (λ1 = λ2, 1, (λ2 + 1)/2,
√
λ2 for for dominant, recessive, additive
models, and multiplicative models). For over-dominant models, λ1 is randomly chosen from (1.001-2), and λ2
from (1.001, λ1).
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Figure 2: The CAT0.5-MAX2 phase digram, with δǫ = ǫ1 − ǫ0 (difference of two HWD coefficients in case
and control group) as the x-axis, and δp = p1 − p0 (difference of allele frequencies in case and control group)
as the y-axis, determined by comparing the empirical power of CAT0.5 and MAX2 tests. More than 10000
disease models are randomly sampled, each is used to randomly generate 5000 replicates of 500 cases and 500
controls. The empirical power of CAT0.5 and MAX2 based on these 5000 replicates are compared when the
type I error is controlled at 0.05. A black circle is drawn when the empirical power of MAX2 is larger than
that of CAT0.5, and a gray circle when CAT0.5 is more powerful than MAX2. If the empirical powers of both
tests are larger than 0.99, a symbol “1” is marked. The two dashed lines form angles of 73.125◦ and 106.875◦
(13π/32 and 19π/32) with the x-axis, or, ±16.875◦ (3π/32) with the y-axis.
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Figure 3: (A) The statistical power of MAX2 as a function of the radius in the δǫ − δp plane,
√
δ2ǫ + δ
2
p. (B)
The statistical power of CAT0.5 as a function of vertical distance to the x-axis, |δp|.
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Figure 4: The CAT0.5-MAX2 phase diagram based on p-value of two tests. 2000 genotype count tables are
simulated using the null model with 500 cases and 500 controls, and A-allele frequency being samples from the
range of (10−5-0.5). If the p-value by MAX2 is smaller (larger) than that by CAT0.5, a black (grey) circle is
drawn. The two dashed lines are the same as those in Fig.2, with angles of 73.125◦ and 106.875◦ (13π/32 and
19π/32) with the x-axis.
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Figure 5: Distribution of datasets in two random sampling of disease models: (1) pA,case is randomly selected
from (0.1, 0.9), and pA,control from (pA,case-0.1, pA,case+0.1). Genotype frequencies in cases and in controls
follow the Hardy-Weinberg equilibrium within the respective group. One replicate of genotype counts is
simulated which is used to calculated the location in phase diagram by Eq.(2). (2) Genotypes aa,Aa,AA in
case group are randomly selected by the interval probabilities: from 0 to L1, from L1 to L2, and from L2 to 1,
where L1 and L2 are sampled from (0.1,0.45) and (0.55, 0.9). The genotype frequencies for control group are
determined by the interval probabilities [0, L′
1
, L′
2
, 1] also, with L′
1
and L′
2
randomly sampled from (L1-0.1,
L1+0.1), (L2-0.1, L2+0.1).
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Figure 6: Distribution of 2147 SNPs on chromosome 18q of a case-control dataset (Amos et al., 2007) on the
δǫ-δp phase diagram. The SNP with the largest allele frequency difference, rs3745064, is marked with a circle.
Note that rs3745064 is not on the y-axis, but inside the first quadrant, indicating that the recessive model
describes its effect better than the multiplicative model.
